cbd chat

December 15, 2021 By admin Off

Coming to Sushant Singh Rajput death case, the CBI is currently trying to probe what part of CBD oil becomes illegal if the TLC levels are higher. The CBI is also trying to probe if it was the illegal substance that Rhea Chakraborty had procured.

As per the WhatsApp chat revealed by the ED, Saha had offered CBD oil to Rhea to be given to Sushant Singh Rajput who was suffering from severe depression and anxiety issues. According to the ED sources, Jaya Saha revealed that the CBD oil she had recommended to Rhea Chakraborty was easily available and was even legal for medicinal use. Saha in the message to Rhea had advised her to give the actor four drops of the oil which would help him relax and keep him calm.

CBD oil is 40% extract of the Cannabis plant and is said to be quite effective in lowering anxiety as well as treating pain. The CBD oil is legal in India, as well as other countries. It is meant to be a pain killer. However, there is no evidence of its effectiveness. The biological effects of the CBD oil have not yet been determined. In India, CBD oil is also largely consumed.

Cannabidiol (CBD) oil, has been mentioned in Rhea Chakraborty’s WhatsApp chat with Jaya Saha, that came to light during the questioning of the actress by the Enforcement Directorate (ED) in connection with the Sushant Singh Rajput death case.

WHAT IS CBD OIL?

CBD oil is 40% extract of the Cannabis plant and is said to be quite effective in lowering anxiety as well as treating pain.

According to Saha’s statement to the ED, the late actor was suffering from severe anxiety and depression. Saha added that the actor suffered repeated bouts of anxiety and on many occasions would become restless. The actor himself had informed Saha about his health condition and she advised Rhea to give doses of the oil to the actor in tea or coffee.

Tyler Marshall, University of Alberta and Jonathan N. Stea, University of Calgary.

Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut.

Professor of Architecture and Urban Design, The University of Melbourne.

CBD sales are soaring, but evidence is still slim that the cannabis derivative makes a difference for anxiety or pain.

Associate Professor of Addiction, University of York.

Michelle Ward, L’Université d’Ottawa/University of Ottawa.

Honorary Professional Fellow, Faculty of Design, Architecture and Building, University of Technology Sydney.

Professor and Chair of Pharmacodynamics, University of Florida.

Amie Hayley, Swinburne University of Technology.

Gary Mortimer, Queensland University of Technology ; Louise Grimmer, University of Tasmania , and Paul J. Maginn, The University of Western Australia.

Pediatricians seeing a growing demand for medical cannabis for kids.

Post-doctoral researcher, UCL.

Paul J. Maginn, The University of Western Australia and Gary Mortimer, Queensland University of Technology.

Professor of Pharmacy Practice, Drake University.

Jenny Wilkerson, University of Florida and Lance McMahon, University of Florida.

CBD and genetic testing provide hope for ‘intractable’ epilepsy in children.

Senior Lecturer in Urban Planning & Design, Monash University.

Professor of Marketing and Consumer Behaviour, Queensland University of Technology.

Assistant Professor of Pharmacodynamics, University of Florida.

Director, Southern Cross Plant Science, Southern Cross University.

Brandon McFadden, University of Delaware and Trey Malone, Michigan State University.

At the time of writing this note there is not an FDA or DEA approved method, though bodies such as the LGC in the UK are working on standardising a method. The issue is that without an internationally recognised test method every lab has a slightly different HPLC methodology and so the same sample if submitted to different labs can have dramatically different CBD and THC levels, which is not due to the cannabinoids, but rather is due to differences in the methods of analysis.

In a recent report by the LGC in the UK a 1 % sample of CBD was sent to over 30 laboratories both regional and international; it was interesting from their report was that a number of the laboratories had gross errors when reporting the sample with range of percentage error being in the 40 to -100 percentage error range.

The issue for growers of hemp etc is that a crop could be deemed illegal if to much THC is in the crop. Similarly products such as CBD oil have to be kept below this level.

CBD – Percentage Error 40 to – 100 %

It is with this understanding that ZP offers HPLC analysis of cannabinoids, including THC and CBD.

The issue with HPLC analysis of CBD in products such as hemp, CBD oils etc is that there is not a single recognised international test procedure.

The legal limit of THC in a product is approximately 0.2 % depending on jurisdiction.

As with CBD there is a significant lab to lab variation when different labs measure the same THC sample. In a recent LGC report, where approximately 31 labs tested the ‘same’ the same THC sample, the range of measured THC values had percentage errors of 65 to -100 %. The problem is that this could be enough to deem a product or crop ‘illegal’ , but the same sample when tested in a different lab could be reported as ‘legal’.

THC – Percentage Error 65 to – 100 %